At the end of life, chemotherapy often does not help, and early palliative care improves quality of life and even survival (Temel 2010).
Original statement
أثبت تيميل (NEJM 2010) أن الرعاية التلطيفية المبكرة لسرطان الرئة المنتشر تحسّن جودة الحياة وتُطيل البقيا (11.6 شهراً مقابل 8.9) رغم تخفيف العلاج الكيماوي
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
At the end of life, chemotherapy often does not help, and early palliative care improves quality of life and even survival (Temel 2010).
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (rule page summary/narrative)
- Origin
- https://eltayebat.com/rule/chemo-radiation/
- Attribution uncertainty
- Written by archive operators; not attributed to Elawady.
- Population concerned
Patients with metastatic or end-stage cancer
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly true – Correct at its core, but with limitations or minor inaccuracies.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Early palliative care improves QoL and prolongs survival despite less aggressive chemotherapy; chemo near death does not improve quality of death.
2. What is demonstrably correct?
Temel's RCT: better QoL (FACT-L 98.0 vs 91.5), fewer depressive symptoms, less aggressive end-of-life care, median survival 11.6 vs 8.9 months (A-CHM-16). Chemotherapy near death did not improve, and in fit patients worsened, quality of death (A-CHM-17); end-of-life overuse is a recognised issue (A-CHM-18).
3. What is wrong or exaggerated?
'Proved ... prolonged survival' overstates a secondary endpoint of one small trial. The abstract reports less aggressive end-of-life care, not generally less chemotherapy; both arms received standard oncologic care. These data concern metastatic/end-stage disease and do not apply to curative treatment.
4. What remains unclear?
Mechanism of the survival effect.
5. Which studies support it?
6. Which studies contradict it?
For curative settings: I-CHM-01, I-CHM-02.
7. What applies to Germany and Europe?
Early palliative care integration is recommended in European oncology (not audited here).
8. What is known about Egypt?
Palliative-care availability may be limited (no data reviewed).
9. What practical conclusion is appropriate?
Ask early for palliative/supportive care alongside cancer treatment; discuss goals of care near the end of life.
Assessment details
- Rationale for certainty of evidence
One RCT (survival secondary) and observational data; consistent with clinical consensus on end-of-life over-treatment.
- Source quality
Correct numbers; overstated wording.
- Regional transferability
Moderate.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
In advanced lung cancer, adding specialised palliative care early improved patients' quality of life and mood, and patients lived somewhat longer. Chemotherapy in the last weeks of life often does not help. These findings support good end-of-life care. They do not mean that chemotherapy is useless in earlier, curable stages.
Studies on this claim
Studies supporting the claim (3)
-
Early palliative care helps patients with advanced lung cancer
Temel JS et al.. N Engl J Med 2010 · PMID 20818875 · DOI 10.1056/NEJMoa1000678Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key studyBetter quality of life, less depression, and longer median survival (11.6 vs 8.9 months) when added to cancer care.
Early palliative care benefit
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test early palliative care.
- How was the study done?
RCT.
- How many people, animals or samples were studied?
151 patients.
- What was actually found?
QoL and mood better; survival longer.
- How large was the observed effect?
+2.7 months median (11.6 vs 8.9 months; calculated).
- What do the results mean in everyday life?
Ask early for palliative/supportive care.
- What are the study's limitations?
Small single-centre trial.
- What does it say about Elawady's specific claim?
Supports palliative care, not refusal of oncology.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
That chemotherapy is useless.
-
Chemotherapy in the last months of life did not improve quality of dying
Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378Cohort studycited by the Tayebat archivefull text checkedIn patients still fit, chemotherapy near death was linked to worse quality of the last week.
End-of-life chemo
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Assess end-of-life chemo.
- How was the study done?
Prospective cohort.
- How many people, animals or samples were studied?
312.
- What was actually found?
No survival or QoD benefit.
- How large was the observed effect?
OR 0.35 (ECOG 1).
- What do the results mean in everyday life?
Discuss goals of care near end of life.
- What are the study's limitations?
Not randomised; chemotherapy users were younger and fitter; only patients who died were analysed; no dose data; caregiver-rated outcome.
- What does it say about Elawady's specific claim?
Supports for end-stage only.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
That chemotherapy is harmful in curative, adjuvant or first-line settings; that chemotherapy never prolongs life in advanced cancer.
-
Too much chemotherapy close to death is a recognised problem
Earle CC et al.. J Clin Oncol 2008 · PMID 18688053 · DOI 10.1200/JCO.2007.15.8253Narrative reviewcited by the Tayebat archiveabstract only checkedReview of chemotherapy overuse and late hospice referral in the USA.
End-of-life overuse
Does the study support the specific claim? Yes · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review end-of-life care.
- How was the study done?
Narrative.
- What was actually found?
Overuse trends.
- What do the results mean in everyday life?
Plan end-of-life care early.
- What are the study's limitations?
Narrative.
- What does it say about Elawady's specific claim?
Supports end-of-life point only.
- Do the results apply to Germany and Europe?
Low-moderate.
- What can explicitly not be concluded from this study?
Curative-setting conclusions.
No study in this group is marked as key.
Studies contradicting or limiting the claim (0)
No studies in this group.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Early palliative care integration is recommended in European oncology (not audited here).
Egypt
Palliative-care availability may be limited (no data reviewed).
What applies in my country?
General scientific assessment
Mostly true Valid for end-of-life care; not transferable to curative treatment.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Early palliative care for patients with metastatic non-small-cell lung cancer.. Temel JS et al.. N Engl J Med 2010 · PMID 20818875 · DOI 10.1056/NEJMoa1000678
- Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.. Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378
- Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?. Earle CC et al.. J Clin Oncol 2008 · PMID 18688053 · DOI 10.1200/JCO.2007.15.8253